Prof Daugherty - CytomX Therapeutics Insider

CytomX Therapeutics Inc -- USA Stock  

USD 21  0.44  2.14%

Founder and Member of Scientific Advisory Board

We currently do not have informatin regarding Prof Daugherty. This executive tanure with CytomX Therapeutics Inc is not currenlty determined.

Management Efficiency

The company has return on total asset (ROA) of (14.12) % which means that it has lost $14.12 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (81.04) % meaning that it created substantial loss on money invested by shareholders.

Entity Summary

CytomX Therapeutics, Inc. operates as an oncologyfocused biopharmaceutical company in the United States. CytomX Therapeutics Inc (CTMX) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 63 people. CytomX Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add CytomX Therapeutics Inc to your portfolio

Top Management

CytomX Therapeutics Inc Leadership Team
Matthew Young, Director, MBA
Hoyoung Huh, Chairman, Ph.D
Marion McCourt, Director
Charles Fuchs, Director
Prof Daugherty, Founder
Rachel Humphrey, Executive
Elaine Jones, Director, Ph.D
Cynthia Ladd, President
Michael Kavanaugh, Executive
Frederick Gluck, Director
Sean DPhil, CEO
Sean McCarthy, CEO, Ph.D
Robert Goeltz, CFO, MBA
Neil Exter, Director, MBA
Timothy Shannon, Director
John Scarlett, Director
Michael MD, Executive
Robert II, CFO
Debanjan Ray, CFO, MBA
W Kavanaugh, Executive

Stock Performance

CytomX Therapeutics Performance Indicators